Kornimate/medical-research-clean huggingface dataset:
study of oral pg-116800 following a heart attack

Conditions: Myocardial Infarction; Heart Failure; Heart Enlargement

Summary: the main purpose of the study is to test whether a possible new drug (called pg-116800) can prevent some of the damage to heart muscle in patients who have had a heart attack. the study will also supply information regarding possible uses of this compound in cardiovascular disease.

heart attacks cause damage to heart muscle that can weaken the heart and lead to changes in the shape and pumping ability of the heart. these changes can lead to heart failure. an enzyme called metalloproteinase (mmp) plays a role in this damage. the main purpose of the study is to test whether a possible new drug (called pg-116800) that interferes with the mmp enzyme can prevent some of the damage to heart muscle in patients who have had a heart attack. the study will also supply information regarding possible uses of this compound in cardiovascular disease. this is a phase ii "proof-of-concept" study; that is, it is a first attempt to treat sick people with the drug to see if it works. the study is interventional since we will be using a drug to interfere with the heart tissue damage that follows a heart attack.

Eligibility criteria:
inclusion: * be at least 18 years of age but not older than 80 years of age at screening; * be diagnosed with a heart attack based on electrocardiogram (ecg) and cardiac enzymes criteria; * the qualifying heart attack has to be a first heart attack; * the qualifying heart attack has to result in a left ventricular ejection fraction (a measure of the working efficiency of the heart) between 15% and 40%. exclusion: * documented previous history of heart attack; * any past history of heart failure; * hemodynamic instability (no instability of circulatory system); * history of congenital heart disease and cardiomyopathy (weakened heart muscle) associated with connective tissue disorders; * recent history or current moderate-to-severe kidney or liver impairment; * significant blood dyscrasias (disorders of the blood cells); * females who are currently: pregnant; breast-feeding; or are of childbearing potential.
monitored saturation post-icu

Conditions: Sleep Apnea, Obstructive; Respiratory Insufficiency

Summary: the overall aim with this project is to describe the correlation between measured and charted saturation after intensive care and also describe the saturation-pattern in these patients. the investigators will also correlate post-icu desaturations measured as oxygen denaturation index and complications to pre-icu obstructive sleep apnea and the stop bang screening questionnaire.


Eligibility criteria:
inclusion criteria: * \>18 years of age. * admitted to the central intensive care unit (civa) * signed informed conscent by the patient or a relative exclusion criteria: -
efficacy of milrinone with sildenafil in persistent pulmonary hypertension in children

Conditions: Persistent Pulmonary Hypertension of the Newborn

Summary: neonates with persistent pulmonary hypertension (pph) should be administered inhaled nitric oxide (ino) and extracorporeal membrane oxygenation (ecmo), but these are not available in most resource-constrained settings like ours. this study was planned to compare the outcomes of milrinone plus sildenafil versus sildenafil alone in the treatment of pph in neonates.


Eligibility criteria:
inclusion criteria: * patients of either gender * aged between 1-28 days * birth weight above 2000 grams * diagnosed with persistent pulmonary hypertension (as per echocardiography) exclusion criteria: * neonates having congenital heart defects (chds) * congenital diaphragmatic hernia * lung anomalies * history of any surgical intervention
safety, tolerability and efficacy study of topical pf-06763809 in subjects with mild to moderate chronic plaque psoriasis

Conditions: Psoriasis

Summary: the study is a randomized, double blinded, vehicle and active comparator controlled, multiple dose study in subjects with chronic plaque psoriasis. the study will have approximately 15 completers. each subjects will receive three different topical doses of pf 06763809, pf 06763809 vehicle, and two active comparators. these will be applied to six different treatment fields for 18 days. the total duration of participation in the study will be approximately 7 weeks (minimum) to approximately 11 weeks (maximum), including the interval from screening to the follow up phone call visit.


Eligibility criteria:
inclusion criteria: * psoriasis vulgaris in a chronic stable phase and with a plaque area of mild to moderate severity sufficient for six treatment fields located in up to three plaque areas * target lesion(s) should be on the trunk or extremities (excluding palms/soles). exclusion criteria: * history of skin sensitivity to topical prescription or non prescription products such as creams, lotions and cosmetics * psoriasis guttata, psoriasis punctata, psoriasis erythrodermatica, and pustular psoriasis * treatment with any biologics within 3 months prior to day 1 of the study and during the study

Keywords: psoriasis topical
remote ischemic preconditioning mechanism study

Conditions: Pain

Summary: this research is being done because pain is a significant problem for patients with a variety of medical problems and following surgery or traumatic injury. currently available pain medications may not relieve all types of pain or may relieve pain only at doses that produce side effects and potential complications. although remote ischemic preconditioning (ripc) appears promising, there remain several unanswered questions about how it works. this research trial will help determine how ripc may activate the bodies natural pain control system. the goals of this study are to see if ripc has any effect 1) on a small area of skin that will be expose to a small amount of uv- b radiation (a mild sunburn), 2) on acute thermal heat temperatures that will be applied to skin, and 3) on the sunburn-like sensation to light touch after putting capsaicin cream (the active ingredient in hot chili peppers) on skin. remote ischemic preconditioning is done by inflating a balloon (very similar to a blood pressure cuff) on the leg until it blocks blood flow for a few minutes. the cuff is then deflated and blood flow resumes. the process is repeated up to three times. this procedure causes the body to increase its natural pain relief system that may help to decrease the amount of postsurgical pain.

the purpose of this pilot study is to determine whether ripc effects peripheral sensitization, central sensitization or both and determine effect size since there is no data regarding the presumed effect. these issues cannot be easily sorted out in patients experiencing postoperative pain and hypersensitivity, since surgery affects both components. in order to address this purpose the investigators will examine, in healthy volunteers, the effect of ripc on a manipulation which generates hypersensitivity by an exclusive peripheral mechanism (ultraviolet b (uv-b) burn) and a manipulation which generates hypersensitivity by an exclusive central mechanism (topical capsaicin). understanding the sites at which ripc reduces the amplification of pain after injury will be useful in determining where it would be most logically applied clinically and in guiding preclinical mechanistic studies.

Eligibility criteria:
inclusion criteria: * healthy volunteers of both sexes asa 1 or ii classification * between the ages of 18-55 * weighing less than 250 pounds * without chronic pain * not taking analgesics * off caffeine for 2 days. exclusion criteria: * pregnancy * allergy to capsaicin * lower extremity vascular insufficiency * active treatment for dvt * severe thigh pain * taking psychotropic medications, including anti-depressants.

Keywords: remote ischemic preconditioning nociception central sensitization peripheral sensitization
copeptin in normal- to hyperosmolar states

Conditions: Copeptin Blood Values

Summary: kinetics of copeptin in response to osmotic alterations in healthy volunteers

construction of the standard area of copeptin release in the normo- and hyperosmolar state and its half-life based on ist decline during hypoosmotic suppression in healthy volunteers.

Eligibility criteria:
inclusion criteria: * minimum age 18 * no severe comorbidities * no medication (except contraceptives) * baseline sodium level 135-145mmol/l * euvolemic status exclusion criteria: * history of heart failure * liver cirrhosis * kidney disease (gfr \<60ml/min) * anemia * uncontrolled hypertension * pregnancy * diabetes mellitus * bmi \>28kg/m2 * other severe disease
rosuvastatin prevent contrast induced acute kidney injury in patients with diabetes

Conditions: Diabetes Mellitus; Chronic Kidney Disease

Summary: the number of cardiac angiography and percutaneous coronary interventions (pci) has increased steadily in recent years. this has resulted in the increasing incidence of contrast-induced acute kidney injury (ciaki). major risk factors for ciaki include older age, diabetes mellitus (dm), chronic kidney disease(ckd), the concurrent use of nephrotoxic drugs, hemodynamic instability, etc. importantly, dm appears to act as a risk multiplier, meaning that in a patient with ckd it amplifies the risk of ciaki. the aim of this multicenter prospective, randomized, controlled study is to evaluate whether statins treatment during the perioperative period would reduce the risk of ciaki in a high-risk population of patients with both type 2 diabetes mellitus (t2dm) and ckd undergoing coronary angiography or noncoronary angiography, and evaluate the influence of such potential benefit on short-term outcome.


Eligibility criteria:
inclusion criteria: * planned diagnostic coronary or peripheral artery angiography * t2dm * ckd stages 2 and 3, egfr 30 to 89ml/min per 1.73m2 * statin naive, or not on statin treatment for at least 14 days * withdrawal metformin or aminophylline for 48h before angiography * total iodixanol volume exclusion criteria: * hypersensitivity to iodine-containing compounds and statins * type 1 diabetes mellitus * ketoacidosis * lactic acidosis * ckd stages 1,4 or 5 (egfr≥90ml/min per 1.73m2 or egfr\<30ml/min per 1.73m2) * stemi * nyha class iv or hemodynamic instability * administration of any iodinated cm within 14 days before randomization * ldl-c\<1.82mmol/l（70mg/dl） * hepatic dysfunction (alt 3 times greater than upper normal limit) * thyreoid insufficiency * renal artery stenosis(unilateral \>70％ or bilateral stenosis\>50％)

Keywords: diabetes mellitus chronic kidney disease contrast induced acute kidney injury angiography
preop laxatives in robotic urologic surgery

Conditions: Prostate Cancer; Kidney Cancer; Constipation

Summary: minimally-invasive surgery, either laparoscopic or robotic, is commonly used in urology. several urologic procedures including prostatectomy, radical nephrectomy, and partial nephrectomy are now commonly performed robotically. patients undergoing these procedures often have delayed return of bowel function and persistent gastrointestinal symptoms including nausea/vomiting, abdominal distension, and bloating for several days to weeks after surgery. postoperative stool softeners and laxatives are routinely used in an effort to minimize these symptoms, with varying degrees of success. the aim of this study will be to evaluate whether the use of a preoperative osmotic laxative will be beneficial in improving recovery of bowel function and alleviating postoperative gastrointestinal complaints in patients undergoing these procedures. patients will be randomized to either receive or not receive three days of polyethylene glycol (peg, also known as miralax) on the three days before surgery. patients in both groups will receive the same postoperative bowel regimen including scheduled peg both in the hospital and upon discharge until first bowel movement. patients will be given a questionnaire and diary to record their postoperative gastrointestinal symptoms and time to first bowel movement. these questionnaires and diaries will then be analyzed to determine differences in time to first bowel movement and gastrointestinal complaints during their recovery from surgery.


Eligibility criteria:
inclusion criteria: -patients 30 years or older undergoing robotic-assisted laparoscopic radical prostatectomy, transperitoneal radical nephrectomy, or transperitoneal partial nephrectomy exclusion criteria: * patients under 30 years old * patients with a contraindication to receiving polyethylene glycol or other forms of laxatives * people who regularly take miralax * patients undergoing retroperitoneal radical or partial nephrectomy * patients with severe ulcerative colitis or crohn's disease * patients with intestinal diversions (colostomy, ileostomy) * patients with prior abdominal or pelvic radiation * patients who will not follow up with uihc postoperatively * patients who are incarcerated
fecal microbiota transplant for recurrent clostridium difficile infection

Conditions: Clostridium Difficile Infection

Summary: the purpose of this research is to investigate the efficacy of transplanting screened donor fecal material in treating patients with recurrent clostridium difficile infection. participants with refractory clostridium difficile infection will be given healthy donor stool administered by colonoscopy or enema and their response will be evaluated by symptom questionnaire and stool testing for clostridium difficile at 4 weeks after the treatment.


Eligibility criteria:
inclusion criteria for recipient: * between the age of 18 and 100 * have positive clostridium difficile polymerase chain reaction (pcr) or toxin * have symptoms of \> 3 watery loose stools a day for at least 2 consecutive days * have failed at least one prior standard course of antibiotic therapy. examples of standard therapy are: * metronidazole 500 mg three times a day for 10 to 14 days * vancomycin 125 mg four times a day for 10 to 14 days * not be pregnant and have negative urine and/or serum human chorionic gonadotropin (hcg) test * not be taking oral or intravenous steroids in the past three months. * not on biologic agents, anti-tumor necrosis factor (anti-tnf) agents, cyclosporine, mercaptopurine, azathioprine, methotrexate or chemotherapy in the preceding 3 months * not have profound immunosuppression: chemotherapy the preceding 3 months, hiv/aids, decompensated cirrhosis * not be in the intensive care unit * not be a transplant recipient exclusion criteria for recipient: * not between the age of 18 and 100 * does not have positive clostridium difficile pcr or toxin * does not have symptoms of \> 3 watery loose stools a day for at least 2 consecutive days * has not failed at least one prior standard course of antibiotic therapy. examples of standard therapy are: * metronidazole 500 mg three times a day for 10 to 14 days * vancomycin 125 mg four times a day for 10 to 14 days * is pregnant * has taken oral or iv steroids in the past three months. * has taken biologic agents, anti-tnf agents, cyclosporine, mercaptopurine, azathioprine, methotrexate or chemotherapy in the preceding 3 months * has profound immunosuppression: chemotherapy the preceding 3 months, hiv/aids, decompensated cirrhosis * in the intensive care unit * is a transplant recipient
the wellness transformation network pilot study

Conditions: Non-Diabetic; Females Who Are Not Pregnant or Breast Feeding

Summary: the purpose of the study is to establish a standard operating procedure (sop) for the screening of pathologies associated with prediabetes and type 2 diabetes.

the proposed study will enable screening of pathologies associated with cardiometabolic diseases (i.e., hypertension, prediabetes, insulin resistance, diabetes, and obesity). the meal-induced insulinemia and glycemia (mig) score will correlate with those dysfunctions that are components of the absence of meal-induced insulinemia (amis) syndrome. overall the study aims: 1. to establish an sop for screening pathologies associated with cardiometabolic diseases using a combination of biometrics and metabolomics. 2. to compare a participant's mig score and hepatalin levels following consumption of a standardized test meal containing macronutrients, and the measurement of several indices of organ health associated with diabetes (i.e., body composition, handgrip strength, spirometry, blood pressure, and heart rate variability). the study will involve 2 study visits: visit 1 - screening and visit 2 - intervention (test meal administration and postprandial blood collection).

Eligibility criteria:
inclusion criteria: * adults (males and females)18 years of age or older. * able to understand and communicate in english. * willing to answer a questionnaire on lifestyle and health status. * willing to undergo measurements of height, weight, waist circumference, hip circumference, blood pressure, heart rate and heart rate variability, body mass index, handgrip strength (handgrip dynamometry) testing, and pulmonary function (spirometry) testing. * willing to fast for 12 hours prior to two in-person study visits. * willing to consume a standardized test meal containing food ingredients. * willing to provide a urine sample. * willing to take a pregnancy test (female participants of childbearing potential). * willing to provide the research team with a listing of all current medications and natural health products(nhps). * willing to complete an online ediary, including a 3-day food record. * willing to give blood samples (finger prick and blood sampling at defined intervals using an intravenous catheter) exclusion criteria: * individuals diagnosed with diabetes. * women with confirmed pregnancy or who are breastfeeding. * individuals with allergy or sensitivity to any component of the standardized test meal (i.e., dextrose, lecithin, soy protein). * individuals with a fasting blood glucose of 7.0 mmol/l or higher. * individuals with abnormal glucose in their urine. * individuals who are related to or working for the clinic site, research staff, and study sponsor.

Keywords: glucose insulin prediabetes
increasing help-seeking in military service members

Conditions: Military Service Members at Elevated Suicide Risk

Summary: there is sufficient evidence that military service members markedly underutilize behavioral health care services, in part, due to stigma. this study proposes to examine a novel application of a cognitive bias modification (cbm) intervention designed to target stigma-related cognitions among service members at elevated suicide risk not currently engaged in behavioral health treatment.

this study proposes to examine a novel application of a cognitive bias modification (cbm) intervention designed to target stigma-related cognitions among service members at elevated suicide risk not currently engaged in behavioral health treatment. interventions that leverage cbm principles involve the completion of brief, web-based tasks in which participants are presented with a series of stimuli (e.g., words, sentences) and trained to respond to those stimuli in a manner that is positive or neutral, rather than negative and unhelpful. consistent with the theoretical rationale for cognitive behavioral therapy, cbm interventions function by reshaping negative cognitions. repeated reinforcement of adaptive cognitions enhances functioning and reduces distress. cbm interventions have efficacy in reducing maladaptive cognitions across a range of psychiatric symptoms. however, limited data exist regarding the use of cbm to target help-seeking stigma cognitions.

Eligibility criteria:
inclusion criteria: * current active duty u.s. military service member * lifetime history of suicidal ideation per a self-report version of the sitbi-sf and/or * current elevated suicide risk factors (i.e., screening positive for clinically significant suicidal ideation \[dsi-ss total score \> 2\], depression \[phq-9 total score \> 14\], anxiety \[gad-7 total score \> 9\], ptsd \[pcl-5 total score \> 32\], alcohol use \[audit-c total score \> 3 for men and \> 2 for women\], and/or anger \[dars total score \> 22\]) * no current behavioral health service use (i.e., ongoing care with a provider to receive psychiatric medications, therapy, and/or counseling) exclusion criteria: * unable to provide informed consent * lack of internet access via a computer, tablet, and/or mobile phone * scheduled to be stationed outside the continental u.s. any time during the 11 weeks following study enrollment (i.e., during the study period) * imminent suicide risk (i.e., suicide risk warranting hospitalization) based on the joiner et al. and chu et al. decision tree framework.

Keywords: suicide prevention reducing stigma
protein supplementation and weight loss

Conditions: Obesity

Summary: this randomized control trial of diet with protein supplementation is being conducted to test the hypothesis that in overweight/obese subjects high protein diet may lead to weight loss and improvement in cardio-metabolic profile.


Eligibility criteria:
inclusion criteria: 1. subjects aged between 21 -65 years 2. subjects with bmi \> 23 kg/m2 exclusion criteria: * inclusion criteria: 1. subjects aged between 21 -65 years 2. subjects with bmi \> 23 kg/m2 exclusion criteria: 1. diabetes (type 1 and type 2) 2. known or documented coronary heart disease (chd) (including ecg consistent with prior myocardial infraction), cerebrovascular accident (including transient ischemic attack), peripheral vascular disease (including symptoms of claudication) 3. angina or other chest pain that may indicate chd by history 4. clinically significant neoplastic, cardiovascular, hepatic, renal, metabolic, endocrine (untreated or unstable), or psychiatric (untreated or unstable) by history 5. medications: lipid lowering therapy, daily nsaid or greater than 325 mg asa (prn use ok), clopidogrel (or equivalent), coumadin, other investigational drugs within 30 days of study entry 6. pregnancy or planning pregnancy during the study period by history 7. uncontrolled hypertension 8. uncontrolled hypothyroidism 9. sensitivity or allergy to product by history 10. subjects who had undergone bypass procedure 11. any debilitating disease such as tuberculosis, hiv by history . 12. unwillingness to give written informed consent for participation in the study